(redirected from 4-hydroxytamoxifen)
Also found in: Thesaurus, Medical, Encyclopedia.


A drug that is a selective estrogen receptor modulator, C26H29NOS, used in the form of its citrate primarily to treat breast cancer in women whose tumors are estrogen-dependent and to prevent breast cancer in high-risk women.

[t(rans)- + am(ino)- + alteration of oxy- + alteration of phen(ol).]


(Pathology) a drug that antagonizes the action of oestrogen and is used to treat breast cancer and some types of infertility in women
[C20: altered from t(rans-) + am(ine) + oxy-2 + phen(ol)]


(təˈmɒk sə fən, -ˌfɛn)

a drug, C26H29NO, that blocks the estrogen receptors on cancer cells, used to treat breast cancer and to prevent recurrence or occurrence of breast cancer in high-risk people.
[1970–75; perhaps t (rans)- + am (ino)- + oxy-2 + phen (yl), with resp. of y and ph]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.tamoxifen - an antagonist for estrogen that is used in the treatment of breast cancer
antagonist - a drug that neutralizes or counteracts the effects of another drug


n tamoxifeno
References in periodicals archive ?
Clearly, the domain of ER model is constrained to phenols, which is consistent with the fact that 4-hydroxytamoxifen was in-domain and ~10 times more potent a binder than either tamoxifen or its citrate salt, which were considered out-of-domain by the model.
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.
for the manufacture of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient in Atossa's leading drug candidate, Afimoxifene gel.
The companies have signed the agreement for the manufacturing of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient (API) in Atossa's leading drug candidate, Afimoxifene Gel.
The randomized, double-blind, phase II study compared transdermal application of a gel containing 4-hydroxytamoxifen (4-OHT), an antiestrogenic metabolite of tamoxifen (4 mg/day), to oral tamoxifen (20 mg/day) in preand postmenopausal women with estrogen receptor--positive ductal carcinoma in situ (DCIS).
SERM; selective estrogen receptor modulator such as tamoxifen (TAM) commonly used in premenopausal survivors Al: aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) used only in postmenopausal survivors to block the conversion of adrenal testosterone to estrogen SSRI: selective serotonin reuptake inhibitor Notes: Tamoxifen-treated patients carrying CYP2D6 variants that impaired formation of 4-hydroxytamoxifen, had more than double the risk of recurrence of breast cancer, shorter reiapse-free periods, and worse event-free survival rates compared with patients with functional CYP2D6.
It highlights the biotransformation of tamoxifen into primary and secondary metabolites with an emphasis on the clinically active metabolites 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen).
One approach to regulate Cre activity utilizes a mutant estrogen hormone binding domain (ERTM) to keep Cre inactive unless the non-steroidal estrogen analog 4-hydroxytamoxifen (4OH-TM) is present (Hayashi and McMahon, 2002) (Figure 4A).